ID: h-056cb87f4e
Hypothesis
NLRP3 Inflammasome Inhibition for Neuroprotection in Parkinson's Disease
Targeted inhibition of NLRP3 inflammasome activation attenuates alpha-synuclein-driven microglial neuroinflammation, reduces IL-1β/IL-18-mediated dopaminergic neuron loss, and may slow PD progression.
EvidencePending (0%)📖 0 cit🗣 1 debates✓ 5 support✗ 3 oppose
✓ All Quality Gates Passed
🧪 Overview
Targeted inhibition of NLRP3 inflammasome activation attenuates alpha-synuclein-driven microglial neuroinflammation, reduces IL-1β/IL-18-mediated dopaminergic neuron loss, and may slow PD progression. Oral CNS-penetrant inhibitors (dapansutrile, NT-0796) have entered Phase 2 trials, representing the most translationally viable anti-inflammatory approach in neurodegeneration.
🧬 Mechanism
No curated mechanism pathway recorded for this hypothesis.
⚖️ Evidence
⚖️ Evidence Matrix5 supports3 contradicts
Supports
Alpha-synuclein fibrils activate NLRP3 in cultured microglia via TLR4/NF-κB priming
Supports
MCC950 inhibitor protects dopaminergic neurons in MPTP and α-syn preformed fibril models
Contradicts
MCC950 has poor CNS penetration and failed toxicology for clinical development
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — NLRP3
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for NLRP3.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↘
Falling
7d Momentum
▼ 1.3%
Volatility
Low
0.0025
Events (7d)
3
Price History
▼16.6%💾 Resource Usage
No resource usage or linked notebooks recorded for this hypothesis yet.
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF male C57BL/6 mice receive oraldapansutrile (30 mg/kg/day) beginning 4 weeks after intrastriatal alpha-synuclein preformed fibril injection (a model of prodromal PD), THEN striatal IL-1β concentrati | Striatal IL-1β concentration reduced by ≥40%; nigral TH+ neuron survival improved by ≥30% versus vehicle controls | — no observation — | pending | 0.55 |
| IF patients with early-stage Parkinson's disease (Hoehn-Yahr stage 1-2) receive oral NT-0796 (200 mg BID) for 52 weeks, THEN their 123I-FP-CIT (DaTscan) binding decline will be ≤30% from baseline comp | DaTscan SPECT binding (putaminal specific binding ratio) decline ≤30% from baseline at week 52 in the active group | — no observation — | pending | 0.35 |
🔮 Falsifiable Predictions (2)
pendingconf 55%
IF male C57BL/6 mice receive oraldapansutrile (30 mg/kg/day) beginning 4 weeks after intrastriatal alpha-synuclein preformed fibril injection (a model of prodromal PD), THEN striatal IL-1β concentration will decrease by ≥40% and substantia nigra TH+ neuron counts will be ≥30% higher compared to vehi
Predicted outcome: Striatal IL-1β concentration reduced by ≥40%; nigral TH+ neuron survival improved by ≥30% versus vehicle controls
Falsification: No statistically significant difference in nigral TH+ neuron counts between inhibitor and vehicle groups (p > 0.05 by unpaired t-test), even if IL-1β is reduced, indicates the primary neuroprotective
pendingconf 35%
IF patients with early-stage Parkinson's disease (Hoehn-Yahr stage 1-2) receive oral NT-0796 (200 mg BID) for 52 weeks, THEN their 123I-FP-CIT (DaTscan) binding decline will be ≤30% from baseline compared to an expected ≥50% decline in historical placebo controls matched for age, disease duration, a
Predicted outcome: DaTscan SPECT binding (putaminal specific binding ratio) decline ≤30% from baseline at week 52 in the active group
Falsification: DaTscan binding decline ≥45% in the active treatment group, indistinguishable from natural disease progression rate, would disprove disease-modifying neuroprotective effect via NLRP3 inhibition
▸Metadatasource: v1_phase_c_backfill · origin_type: debate_synthesizer
| source | v1_phase_c_backfill |
| origin_type | debate_synthesizer |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.